Program
DII235
A development code.
In Novartis's pipeline, siRNA targeting Lp(a) MRNA
. Its studies are mostly in Cardiovascular Diseases, led by Novartis.
Furthest: phase 2, since Nov 14, 20251 company-led study, 1 open or runningNext primary completion: Apr 26, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 11 open or running | phase 2since Nov 14, 2025 | Nov 14, 2025 | Apr 26, 2027phase 2 · NCT07235046 |
- Named in Novartis’s own pipeline as
DII235
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 14, 2025First study: phase 2 study in Cardiovascular DiseasesFirst studyNCT07235046 · 234 enrolled · United States, China, Germany and more
Ahead
- Apr 26, 2027Primary completion: phase 2 study in Cardiovascular DiseasesNCT07235046
TargetBeta
“siRNA targeting Lp(a) MRNA”the company's pipeline, read by Claude · source
Other programs on LPA
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07235046Cardiovascular Diseases · United States, China, Germany and more | 2 | Active, not recruiting | Apr 26, 2027 | 234 |
How it is read
Names in the registry
- “DII235”, 1 entry
Codes read as this program: DII235.
Conditions, from the studies’ own filings
- Cardiovascular Diseases, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.